Literature DB >> 9398810

Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects.

K H Gan1, W P Geus, C B Lamers, H G Heijerman.   

Abstract

There is a lack of information about the effect of omeprazole or other antisecretory drugs on intraduodenal pH. Aim of the study was to document the variation over time of intraduodenal pH during a 24-hr period and to simultaneously study the effect of omeprazole 40 mg once daily on intragastric and intraduodenal pH in healthy H. pylori-negative subjects. In a randomized, placebo-controlled study, eight subjects (five women, three men, mean age 22.7 years) received oral 40 mg omeprazole or placebo once daily for eight days. On day 7, intragastric and intraduodenal pH was measured continuously for 24 hr, using two miniature glass-membrane electrodes placed in the stomach (fundus) and in the distal third of the duodenum. The 24-hr median intraduodenal pH was 5.95 with placebo and 5.85 with omeprazole. Median intragastric pH was 1.68 without and 4.93 with omeprazole. During omeprazole therapy, intragastric pH fell below 4.0 in five of eight subjects. In the 2- and 3-hr postprandial periods, the percentage of time with pH < 5 was significantly reduced with omeprazole. In healthy subjects, 24-hr median and postprandial pH in the distal part of the duodenum was lower than previously thought. Omeprazole significantly reduced the percentage of time with pH < 5 postprandially. At night, intragastric pH fell below 4.0 with omeprazole 40 mg once daily. Omeprazole does not change 24-hr median intraduodenal pH significantly.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398810     DOI: 10.1023/a:1018827003641

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

Review 1.  Omeprazole.

Authors:  P N Maton
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

2.  Influence of exocrine pancreatic insufficiency on the intraluminal pH of the proximal small intestine.

Authors:  S K Dutta; R M Russell; F L Iber
Journal:  Dig Dis Sci       Date:  1979-07       Impact factor: 3.199

3.  Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease.

Authors:  D Y Graham; P D Klein; A R Opekun; T W Boutton
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

4.  Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects.

Authors:  C Cederberg; K Röhss; P Lundborg; L Olbe
Journal:  Scand J Gastroenterol       Date:  1993-02       Impact factor: 2.423

5.  Does long-term inhibition of gastric acid secretion with omeprazole lead to small intestinal bacterial overgrowth?

Authors:  G F Nelis; A H Engelage; G Samson
Journal:  Neth J Med       Date:  1994-09       Impact factor: 1.422

6.  Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.

Authors:  S Hurlimann; B Abbühl; W Inauen; F Halter
Journal:  Aliment Pharmacol Ther       Date:  1994-04       Impact factor: 8.171

7.  Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study.

Authors:  J G Coghlan; D Gilligan; H Humphries; D McKenna; C Dooley; E Sweeney; C Keane; C O'Morain
Journal:  Lancet       Date:  1987-11-14       Impact factor: 79.321

8.  Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.

Authors:  C Cederberg; A B Thomson; V Mahachai; J A Westin; P Kirdeikis; D Fisher; L Zuk; B Marriage
Journal:  Gastroenterology       Date:  1992-09       Impact factor: 22.682

Review 9.  Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.

Authors:  W Creutzfeldt
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

10.  Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas.

Authors:  H Kopelman; M Corey; K Gaskin; P Durie; Z Weizman; G Forstner
Journal:  Gastroenterology       Date:  1988-08       Impact factor: 22.682

View more
  10 in total

Review 1.  Human pancreatic exocrine response to nutrients in health and disease.

Authors:  J Keller; P Layer
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 2.  The impact of proton pump inhibitors on the human gastrointestinal microbiome.

Authors:  Daniel E Freedberg; Benjamin Lebwohl; Julian A Abrams
Journal:  Clin Lab Med       Date:  2014-09-24       Impact factor: 1.935

3.  Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.

Authors:  Hsiu-Chi Cheng; Bor-Shyang Sheu
Journal:  World J Gastrointest Endosc       Date:  2011-03-16

4.  Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers.

Authors:  Ahmad Y Abuhelwa; Stuart Mudge; Richard N Upton; David J R Foster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.441

5.  Proton-pump inhibitors associated with decreased urinary citrate excretion.

Authors:  Parth M Patel; Alexander M Kandabarow; Eseosa Aiwerioghene; Enrique Blanco-Martinez; Spencer Hart; David J Leehey; Ahmer Farooq; Kristin G Baldea; Thomas M T Turk
Journal:  Int Urol Nephrol       Date:  2020-11-18       Impact factor: 2.370

6.  Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.

Authors:  David Y Graham; Aylin Tansel
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-28       Impact factor: 11.382

7.  Association of Proton Pump Inhibitor Therapy with Hepatic Encephalopathy in Hepatitis B Virus-related Acute-on-Chronic Liver Failure.

Authors:  Zhao-Ni Lin; Yong-Qing Zuo; Peng Hu
Journal:  Hepat Mon       Date:  2014-04-07       Impact factor: 0.660

8.  Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.

Authors:  David S Small; Jane Royalty; Ellen A Cannady; Christine Hale; Ming-Dauh Wang; Delyn Downs; Jeffrey G Suico
Journal:  Pharmacotherapy       Date:  2016-07-08       Impact factor: 4.705

9.  Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study.

Authors:  Cheol Min Shin; Nayoung Kim; Yong Sung Kim; Ryoung Hee Nam; Ji Hyun Park; Dong Ho Lee; Yeong-Jae Seok; Yeon-Ran Kim; Joo-Hyon Kim; Jung Min Kim; Joo Sung Kim; Hyun Chae Jung
Journal:  Gut Liver       Date:  2016-11-15       Impact factor: 4.519

10.  Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.

Authors:  Dorien Groenendaal-van de Meent; Martin den Adel; Jan van Dijk; Begona Barroso-Fernandez; Rachid El Galta; Georg Golor; Marloes Schaddelee
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.